SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Mersana Therapeutics, Inc. (MRSN) , 前瞻盈利收益率 4.33%.
本页证实的标准:
- VALUE (10/100, 未通过) — 分析师共识目标价暗示当前价格存在下行风险 ($3.00, 89.7%).
- 前瞻市盈率 23.1
- 分析师共识目标价 $3.00 (-89.7% 下行风险) — 分析师认为当前价格水平存在明显下行风险。
SharesGrow 综合评分： 34/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
✗
价值
10/100
Price-to-Earnings & upside
Proven by this page
~
健康
50/100
Debt-to-Equity & liquidity
→ Health
估值概览 — MRSN
估值倍数
P/E (TTM)0.0
前瞻 P/E23.1
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率87.99
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.56
前瞻 EPS（预估）$1.26
每股账面价值$0.00
每股营收$0.33
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
Forward Earnings Yield4.33%
股息收益率0.00%
分析师目标价$3.00 (-89.7%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2015 |
$-0.94 |
$10.36M |
$-16.43M |
-158.6% |
| 2016 |
$-0.78 |
$25.17M |
$-13.7M |
-54.4% |
| 2017 |
$-3.22 |
$17.55M |
$-38.71M |
-220.6% |
| 2018 |
$-2.79 |
$10.59M |
$-64.26M |
-606.5% |
| 2019 |
$-0.63 |
$42.12M |
$-27.2M |
-64.6% |
| 2020 |
$-1.44 |
$828K |
$-88.4M |
-10676.8% |
| 2021 |
$-2.40 |
$43K |
$-169.21M |
-393500% |
| 2022 |
$-2.22 |
$26.58M |
$-207.54M |
-780.8% |
| 2023 |
$-1.48 |
$36.86M |
$-171.67M |
-465.8% |
| 2024 |
$-0.56 |
$40.5M |
$-69.19M |
-170.9% |
